Ruixi Li,1 Lulu Liu,1 Yong Liu,1 Jiang Tang,1 Jinsong Li2 

1Yueyang Guangji Hospital, Yueyang, Hunan, People’s Republic of China; 2Department of Spine Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan, People’s Republic of China

Correspondence: Jinsong Li, Department of Spine Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan, People’s Republic of China, Tel +86-731-88618826, Fax +86-731-88618526, Email jinsongli_csu@163.com

Introduction: Protocadherin 9 (PCDH9), a member of the cadherin superfamily of transmembrane proteins, plays a role in cell adhesion and neural development. Recent studies suggest that PCDH9 may function as a tumor suppressor in certain cancers, though its specific role in breast cancer remains unclear.
Methods: UALCAN database to retrieve information on PCDH9 expression in breast cancer tissues compared with that in normal tissues. The biological effects of PCDH9 in breast cancer cells were analyzed using the DepMap database. Stable knockdown or overexpression of PCDH9 in breast cancer cell lines and subsequently assessed tumor cell proliferation and migration. Synthetic lethal screening was conducted for breast cancer cells with low PCDH9 expression or deficiency.
Results: In this study, we observed significant downregulation of PCDH9 in breast cancer tissues, with its expression negatively correlated with progression-free survival. Further investigations revealed that decreased PCDH9 expression promotes breast cancer cell proliferation and migration, while overexpression of PCDH9 has the opposite effect. Subsequently, we identified the TAS-102, an approved drug for metastatic colorectal cancer, exhibited selective cytotoxicity against breast cancer cells with low PCDH9 expression.
Conclusion and discussion: In summary, our study identified PCDH9 as a tumor suppressor in breast cancer and highlighted TAS-102 as a potential therapeutic option for tumors with low PCDH9 expression or deficiency. The specific interaction between TAS-102 and PCDH9 warrants further exploration, providing deeper insights into its mode of action in treating PCDH9-deficient breast cancer.

Keywords: breast cancer, PCDH9, synthetic lethality, TAS-102